Shrier Wealth Management LLC Takes Position in Pfizer Inc. $PFE

Shrier Wealth Management LLC bought a new stake in Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 45,113 shares of the biopharmaceutical company’s stock, valued at approximately $1,123,000.

Several other large investors also recently bought and sold shares of the stock. Brighton Jones LLC grew its position in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its holdings in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. United Bank raised its holdings in Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after acquiring an additional 6,415 shares in the last quarter. Loomis Sayles & Co. L P lifted its stake in Pfizer by 9.5% in the second quarter. Loomis Sayles & Co. L P now owns 9,152 shares of the biopharmaceutical company’s stock worth $222,000 after acquiring an additional 794 shares during the last quarter. Finally, VestGen Advisors LLC grew its holdings in Pfizer by 3.0% during the 2nd quarter. VestGen Advisors LLC now owns 38,400 shares of the biopharmaceutical company’s stock worth $931,000 after acquiring an additional 1,123 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Fresh real‑world data from Pfizer’s Swedish observational study on Ibrance (palbociclib) is being framed as a positive signal for the drug’s real‑world effectiveness and market durability, which could support oncology revenue expectations. Pfizer’s Swedish Ibrance Study
• Positive Sentiment: Heightened media and retail investor attention around Pfizer’s GLP‑1/weight‑loss pipeline (including coverage noting share strength despite a high‑profile “pass” comment) is boosting sentiment—investors are pricing potential upside from a once‑monthly treatment. Pfizer’s (PFE) Shares Up Since Jim Cramer Said “Pass”
• Positive Sentiment: Dividend appeal remains a tailwind for income investors—Pfizer is regularly cited among large caps with attractive dividends, supporting buy‑and‑hold interest. Pfizer – Among the 15 Large Cap Stocks with Highest Dividends
• Neutral Sentiment: Retail and institutional attention is elevated (high search/coverage), which can amplify moves but doesn’t guarantee direction — monitor whether flow sustains. Investors Heavily Search Pfizer Inc. (PFE)
• Neutral Sentiment: Broader sector moves (e.g., large deals and AI partnerships at peers) are reshaping investor rotation in healthcare but are not direct Pfizer catalysts; they do, however, affect relative valuation dynamics. Eli Lilly Ramps Up AI Ambitions
• Negative Sentiment: Fundamentals still carry risk: quarterly revenue was slightly down year‑over‑year even as EPS beat estimates, and Pfizer faces stiff competition in the GLP‑1/weight‑loss space from larger early movers—both could cap upside if execution or pricing weakens.

Pfizer Stock Up 1.1%

Pfizer stock opened at $28.08 on Wednesday. The company has a market capitalization of $159.67 billion, a P/E ratio of 20.65 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $28.31. The stock has a 50-day simple moving average of $26.94 and a 200-day simple moving average of $25.75.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.63 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of analyst reports. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a report on Wednesday, February 4th. Royal Bank Of Canada started coverage on Pfizer in a report on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 target price on the stock. Citigroup began coverage on Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price target on the stock. UBS Group initiated coverage on Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price objective for the company. Finally, Daiwa Securities Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective on the stock. in a report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $28.19.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.